The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12)
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea. Materials and methods: We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12. months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients). Results: Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance. Conclusion: The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.
Abstract
Purpose: We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea. Materials and methods: We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12. months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients). Results: Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance. Conclusion: The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.
참고문헌 (26)
- Nathoo N, "Pathobiology of brain metastases", J Clin Pathol, 58, pp.237~242 (2005)
- Ostrom QT, "Brain metastases : epidemiology", Handb Clin Neurol, 149, pp.27~42 (2018)
- Cagney DN, "Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy : a population-based study", Neuro Oncol, 19, pp.1511~1521 (2017)
- Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- Witzel I, "Breast cancer brain metastases : biology and new clinical perspectives", Breast Cancer Res, 18, pp.8~ (2016)
- Brown PD, "Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy : a randomized, double-blind, placebo-controlled trial", Neuro Oncol, 15, pp.1429~1437 (2013)
- Gondi V, "Hippocampal-sparing whole-brain radiotherapy : a"how-to"technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy", Int J Radiat Oncol Biol Phys, 78, pp.1244~1252 (2010)
- Aoyama H, "Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases : a randomized controlled trial", JAMA, 295, pp.2483~2491 (2006)
- Chang EL, "Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation : a randomised controlled trial", Lancet Oncol, 10, pp.1037~1044 (2009)
- Brown PD, "Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases : a randomized clinical trial", JAMA, 316, pp.401~409 (2016)
- Kim JS, "Evolving treatment strategies of brain metastases from breast cancer : current status and future direction", Ther Adv Med Oncol, 12, pp.1758835920936117~ (2020)
- Gampenrieder SP, "Treatment landscape for patients with HER2-positive metastatic breast cancer : a review on emerging treatment options", Cancer Manag Res, 12, pp.10615~10629 (2020)
- Schettini F, "Overall survival of CDK4", 6-inhibitor-based treatments in clinically relevant subgroups of metastatic breast cancer : systematic review and meta-analysis, 2020, pp.112, 1089~1097
- Liu ZB, "Combination strategies of checkpoint immunotherapy in metastatic breast cancer", Onco Targets Ther, 13, pp.2657~2666 (2020)
- Morikawa A, "Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients : a prospective study", Neuro Oncol, 17, pp.289~295 (2015)
- Lin NU, "Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial", J Clin Oncol, 38, pp.2610~2619 (2020)
- Kim JS, "Survival outcomes of breast cancer patients with brain metastases : a multicenter retrospective study in Korea(KROG 16-12)", Breast, 49, pp.41~47 (2020)
- Sperduto PW, "Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases", Int J Radiat Oncol Biol Phys, 82, pp.2111~2117 (2012)
- Nieder C, "Presentation, patterns of care, and survival in patients with brain metastases : what has changed in the last 20 years?", Cancer, 117, pp.2505~2512 (2011)
- Saraf A, "Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development", J Neurooncol, 134, pp.453~463 (2017)
- Hadjipanteli A, "Breast cancer brain metastasis : the potential role of MRI beyond current clinical applications", Cancer Manag Res, 12, pp.9953~9964 (2020)
- Cagney DN, "Implications of screening for brain metastases in patients with breast cancer and non-small cell lung cancer", JAMA Oncol, 4, pp.1001~1003 (2018)
- Barbour AB, "Radiation therapy practice patterns for brain metastases in the United States in the stereotactic radiosurgery era", Adv Radiat Oncol, 5, pp.43~52 (2020)
- Gullhaug A, "Use of radiotherapy in breast cancer patients with brain metastases : a retrospective 11-year single center study", J Med Imaging Radiat Sci, 52, pp.214~222 (2021)
- Kocher M, "Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases : results of the EORTC 22952-26001 study", J Clin Oncol, 29, pp.134~141 (2011)
- Kim JS, "New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients : the significance of molecular subtypes(KROG 16-12)", Breast Cancer Res Treat, 186, pp.453~462 (2021)